Last €40.43 EUR
Change Today +0.199 / 0.49%
Volume 150.0
As of 9:39 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

nps pharmaceuticals inc (NPM) Snapshot

Open
€40.28
Previous Close
€40.23
Day High
€40.82
Day Low
€39.85
52 Week High
01/23/15 - €41.48
52 Week Low
04/15/14 - €16.39
Market Cap
4.3B
Average Volume 10 Days
313.9
EPS TTM
--
Shares Outstanding
106.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NPS PHARMACEUTICALS INC (NPM)

nps pharmaceuticals inc (NPM) Related Businessweek News

View More BusinessWeek News

nps pharmaceuticals inc (NPM) Details

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The company also develops Natpara that is under Phase 3 clinical trial for the treatment of adult hypoparathyroidism; NPSP790 and NPSP795 calcilytic compounds, which are in Phase 1 clinical trial for application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria; and Teduglutide that is under preclinical stage for pediatric indications. It has collaborative agreements with GlaxoSmithKline to collaborate on the research, development, and commercialization of calcium receptor active compounds to treat osteoporosis and other bone metabolism disorders; and Kyowa Hakko Kirin Co. Ltd. to develop and commercialize compounds for the treatment of hyperparathyroidism. The company was founded in 1986 and is based in Bedminster, New Jersey.

207 Employees
Last Reported Date: 02/18/14
Founded in 1986

nps pharmaceuticals inc (NPM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $413.7K
Senior Vice President and President of NPS Ph...
Total Annual Compensation: $395.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $407.9K
Vice President of Corporate Development & Str...
Total Annual Compensation: $223.1K
Compensation as of Fiscal Year 2013.

nps pharmaceuticals inc (NPM) Key Developments

NPS Pharmaceuticals, Inc. Announces FDA Approval of Natpara® (parathyroid hormone) for Injection as an Adjunct to Calcium and Vitamin D to Control Hypocalcemia in Patients with Hypoparathyroidism

NPS Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Natpara® (parathyroid hormone) as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Hypoparathyroidism is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone, or PTH. Natpara, a bioengineered replica of human PTH, is expected to be available in the second quarter of 2015. Because of the potential risk of osteosarcoma, Natpara is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. Natpara was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations or in patients with acute post-surgical hypoparathyroidism. Hypoparathyroidism is a rare endocrine disorder in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone (PTH) or where the hormone lacks biologic activity. PTH plays a central role in a variety of critical physiological functions in the body. Insufficient levels of PTH lead to low levels of calcium and high levels of phosphate in the blood, and an inability to convert native vitamin D into its active state, which helps the body properly absorb oral calcium. Parathyroid hormone increases serum calcium by increasing renal tubular calcium reabsorption, increasing intestinal calcium absorption (i.e., by converting native vitamin D (25 OH) into its active form (1,25 OH2 vitamin D)) and by increasing bone turnover which releases calcium into the circulation. The FDA approval of Natpara was supported by 12 pharmacology studies and four company-sponsored efficacy and safety studies. The pivotal Phase 3 study, known as REPLACE, was a randomized, double-blind, placebo-controlled study and the large clinical trial conducted to date in patients with hypoparathyroidism. Patients with hypoparathyroidism may benefit from having a replica of the actual human parathyroid hormone molecule that they are lacking,â said Tamara Vokes, MD, professor of medicine at the University of Chicago, and program director of the University of Chicago Fellowship Training Program in Diabetes, Endocrinology and Metabolism. â In clinical studies, Natpara has been shown to control hypocalcemia in patients with hypoparathyroidism and reduce their need for oral calcium and active vitamin D. Natpara will be made available through a Risk Evaluation and Mitigation Strategy (REMS) Program to mitigate the potential risk of osteosarcoma.

NPS Pharmaceuticals, Inc., Shire plc - M&A Call

To discuss on Shire plc and NPS Pharmaceuticals, Inc. merger agreement

NPS Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 12:40 PM

NPS Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 12:40 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: Francois Nader, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NPM:GR €40.43 EUR +0.199

NPM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NPM.
View Industry Companies
 

Industry Analysis

NPM

Industry Average

Valuation NPM Industry Range
Price/Earnings 100.0x
Price/Sales 23.3x
Price/Book 37.5x
Price/Cash Flow 4,726.5x
TEV/Sales 21.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NPS PHARMACEUTICALS INC, please visit www.npsp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.